← Back to patent-cliff list
Oxybutynin Hydrochloride (Hisamitsu)
Tier C — Watch / tradeOxybutynin Hydrochloride (Hisamitsu)
Hisamitsu Pharmaceutical Co., Inc.
Originator
2023
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：mAChRs
Indications (approved)：Hyperhidrosis
Regional status
US
-
EU
-
China
-
Japan
Approved
2023-03-27
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Oxybutynin Hydrochloride (Hisamitsu)?
Approved indications include: Hyperhidrosis.
When does the Oxybutynin Hydrochloride (Hisamitsu) patent expire?
No public expiry year is available for Oxybutynin Hydrochloride (Hisamitsu) yet; this page updates once verified.
How do I get a quote for Oxybutynin Hydrochloride (Hisamitsu) intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-27